PD-L1/CD274 Rabbit Monoclonal Antibody (PE)

Programmed cell death 1 ligand 1 (PD-L1), also known as B7-H1 or CD274, is a B7 family protein that is involved in regulation and attenuation of the adaptive immune response and peripheral T cell tolerance.^1,2,3,4 It is a 290-amino acid type I transmembrane protein encoded by CD274 in humans and is composed of a 239-amino acid extracellular domain consisting of a signal peptide, an IgV-like domain, and an IgC-like domain, a transmembrane domain, and a cytoplasmic tail.^1,5 PD-L1 is constitutively expressed in T and B cells, dendritic cells, macrophages, and regulatory T cells (Tregs), as well as a variety of nonhematopoietic cells, and is upregulated by IFN-γ.³ Binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1), suppresses T cell proliferation, migration, and cytokine production.^2,4 PD-L1 is also aberrantly expressed in a variety of tumor cells, and expression of PD-L1 in tumor tissue is associated with poor prognosis in patients with renal cell carcinoma.^6,7,8 Formulations containing PD-L1 blocking antibodies have been used in the treatment of a variety of cancers. Cayman’s PD-L1/CD274 Rabbit Monoclonal Antibody (PE) is composed of a PD-L1/CD274 monoclonal antibody conjugated to phycoerythrin (PE) and can be used for flow cytometry.

WARNING This product is not for human or veterinary use.

1. Fabrizio, F.P., Trombetta, D., Rossi, A., et al. Gene code CD274/PD-L1: From molecular basis toward cancer immunotherapy. Ther. Adv. Med. Oncol. 10, (2018).

2. Riley, J.L. PD-1 signaling in primary T cells. Immunol. Rev. 229(1), 114-125 (2009).

3. del Rio, M.L., Buhler, L., Gibbons, C.E., et al. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl. Int. 21(11), 1015-1028 (2008).

4. Akinleye, A., and Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J. Hematol. Oncol. 12(1), 92 (2019).

5. Keir, M.E., Butte, M.J., Freeman, G.J., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).

6. Ji, M., Liu, Y., Li, Q., et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J. Transl. Med. 13, 5 (2015).

7. Thompson, R.H., Dong, H., Lohse, C.M., et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13(6), 1757-1761 (2007).

8. Thompson, R.H., Kuntz, S.M., Leibovich, B.C., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006).